- Anyone who owns Sangamo BioSciences (SGMO), might want to take a trip over to TheStreetSweeper and check out their piece entitled "A fiery biotech with a product poised to go down in flames?"
- The article questions the company's ZFN gene modification technology which is behind SB-728-T (see recent announcement of new data from Phase 2 trial).
- Senior investigative reporter Sonya Colberg says "TheStreetSweeper would be astounded if SGMO produces a marketable anti-HIV product — ever."
- Notably, Colberg also says "renowned HIV doctor" Joseph Sonnabend was consulted for the article and after reviewing "trial results and graphs," concluded that "no meaningful evidence was presented to indicate that [SGMO's] treatment has antiviral activity."
- See also: SGMO offers shares
From other sites
at CNBC.com (Jan 9, 2015)
at CNBC.com (Sep 9, 2014)
at CNBC.com (Apr 24, 2014)
at CNBC.com (Apr 10, 2014)
at CNBC.com (Mar 6, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs